+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Exploratory Analysis of Prognostic and Predictive Factors of Lenvatinib for Radioiodine-Refractory Differentiated Thyroid Cancer



Exploratory Analysis of Prognostic and Predictive Factors of Lenvatinib for Radioiodine-Refractory Differentiated Thyroid Cancer



International Journal of Radiation Oncology*biology*physics 100(5): 1386-1387




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 065102001

Download citation: RISBibTeXText

DOI: 10.1016/j.ijrobp.2017.12.204


Related references

Exploratory analysis of prognostic factors for lenvatinib in radioiodine-refractory differentiated thyroid cancer. Head and Neck 2019, 2019

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial. Thyroid 27(9): 1135-1141, 2017

Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer. Cancer Science 106(12): 1714-1721, 2016

Exposure-response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer. Cancer ChemoTherapy and Pharmacology 82(6): 971-978, 2018

Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer. Journal of Oncology Pharmacy Practice 24(1): 28-32, 2016

Lenvatinib in Advanced Radioiodine-Refractory Thyroid Cancer - A Retrospective Analysis of the Swiss Lenvatinib Named Patient Program. Journal of Cancer 9(2): 250-255, 2018

Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer. Seminars in Oncology 2019, 2019

Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer. Thyroid 27(8): 1043-1052, 2017

Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial. Journal of Clinical Oncology 35(23): 2692-2699, 2017

Pharmacological and clinical profile of lenvatinib (E-7080) in the treatment of advanced, radioiodine-refractory, differentiated thyroid cancer. Drugs of Today 51(12): 689-694, 2016

Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer. European Journal of Cancer 106: 61-68, 2018

A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer 121(16): 2749-2756, 2015

Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer. Clinicoeconomics and Outcomes Research 8: 323-333, 2016

New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond. Anti-Cancer Drugs 26(7): 689-697, 2015

Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas. Oncologist 21(1): 50-58, 2016